The CALYM Carnot Institute (Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field) is an academic research consortium focusing in lymphoma treatments and diagnosis spanning from new target identification to large international Phase III clinical trials and beyond. CALYM brings together 20 entities with complementary expertise in preclinical, translational and clinical lymphoma research: the Lymphoma Study Association (LYSA), the Lymphoma Academic Research Organisation (LYSARC), and 18 public preclinical research teams in lymphoma based at universities and hospitals across France. The consortium aims at accelerating innovation and its transfer in the lymphoma field, particularly in the translational phase and in the areas of therapeutic, diagnosis and imaging.
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| |
rdfs:comment
| - The CALYM Carnot Institute (Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field) is an academic research consortium focusing in lymphoma treatments and diagnosis spanning from new target identification to large international Phase III clinical trials and beyond. CALYM brings together 20 entities with complementary expertise in preclinical, translational and clinical lymphoma research: the Lymphoma Study Association (LYSA), the Lymphoma Academic Research Organisation (LYSARC), and 18 public preclinical research teams in lymphoma based at universities and hospitals across France. The consortium aims at accelerating innovation and its transfer in the lymphoma field, particularly in the translational phase and in the areas of therapeutic, diagnosis and imaging. (en)
|
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
Link from a Wikipage to an external page
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
has abstract
| - The CALYM Carnot Institute (Consortium for the Acceleration of Innovation and its Transfer in the Lymphoma Field) is an academic research consortium focusing in lymphoma treatments and diagnosis spanning from new target identification to large international Phase III clinical trials and beyond. CALYM brings together 20 entities with complementary expertise in preclinical, translational and clinical lymphoma research: the Lymphoma Study Association (LYSA), the Lymphoma Academic Research Organisation (LYSARC), and 18 public preclinical research teams in lymphoma based at universities and hospitals across France. The consortium aims at accelerating innovation and its transfer in the lymphoma field, particularly in the translational phase and in the areas of therapeutic, diagnosis and imaging. The CALYM Carnot institute is managed by Bertrand Nadel. The steering committee of CALYM consortium is led by Guillaume Cartron. Carnot Institute is a label of excellence awarded by the French Ministry of Research to public-parapublic research institutes with a strong track record of partnering research. (en)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is Wikipage redirect
of | |
is foaf:primaryTopic
of | |